How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?

References 

1. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br. J. Psychiatry. 2001;179:290–299
   • MEDLINE
2. Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt?. J. Clin. Psychiatry. 2001;62:855–859
   • MEDLINE
3. Byerly M, Fischer R, Rush A. A comparison of clinician vs. electronic monitoring of antipsychotic adherence in schizophrenia. In: Presented at the 41st annual meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico. 2002;
4. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–125
   • Abstract
   • Full Text
   • Full-Text PDF (255 KB)
5. Dibonaventura M, Chapman GB. Do decision biases predict bad decisions? Omission bias, naturalness bias, and influenza vaccination. Med. Decis. Making. 2008;28:532–539
6. Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br. J. Psychiatry. 2009;195:s29–s36
7. Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomized controlled trials and observational studies. Br. J. Psychiatry. 2009;195:s20–s28
8. Hamann J, Pfeiffer H, Leucht S, Kissling W. Are patients with schizophrenia under-treated with second-generation antipsychotics? A pilot study of the prescription practices of German psychiatrists. Pharmacopsychiatry. 2003;36(6):309–312
   • MEDLINE
9. Hamann J, Leucht S, Kissling W. Shared decision making in psychiatry. Acta Psychiatr. Scand. 2003;107:403–409
   • MEDLINE
10. Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J. Clin. Psychiatry. 2006;67:1948–1953
11. Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. Int. Clin. Psychopharmacol. 2007;22:275–282
12. Jaeger M, Rössler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res. 2010;1–2:58–62
13. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol. Med. 2003;33:83–89
    • MEDLINE
14. Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: mind the gap. Br. J. Psychiatry. 2009;195:s1–s4
15. Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS, in press. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5years. J. Psychopharmacol.doi:10.1177/0269881109104882.
16. Sim K, Su A, Ungvari GS, Fujii S, Yang SY, Chong MY, et al. Depot antipsychotic use in schizophrenia: an East Asian perspective. Hum. Psychopharmacol. 2004;19(2):103–109
    • MEDLINE